Eagle’s Eye View: Your Weekly CV Update from ACC.org (Week of Oct. 17)
In this week’s View, Dr. Eagle discusses the TIME Study, a prospective, randomized, open-label, blinded-endpoint clinical trial exploring cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives, then looks at phenotyping the hypertensive heart. Finally, Dr. Eagle takes a look at a multinational study on programmed ventricular stimulation as an additional primary prevention risk stratification tool in arrhythmogenic right ventricular cardiomyopathy.
Clinical Topics: Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Noninvasive Imaging, Prevention, Atherosclerotic Disease (CAD/PAD), Implantable Devices, EP Basic Science, Genetic Arrhythmic Conditions, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Echocardiography/Ultrasound, Magnetic Resonance Imaging, Hypertension
Keywords: Antihypertensive Agents, Blood Pressure, Time and Motion Studies, Hypertension, Myocardial Infarction, Diabetes Mellitus, Stroke, Hypertrophy, Left Ventricular, Stroke Volume, Gadolinium, Calcium Channel Blockers, Heart Failure, Atrial Fibrillation, Coronary Artery Disease, Cardiomyopathy, Hypertrophic, Echocardiography, Magnetic Resonance Imaging, Fibrosis, Angiotensin-Converting Enzyme Inhibitors, Angiotensins, Arrhythmogenic Right Ventricular Dysplasia, Ventricular Premature Complexes, Defibrillators, Implantable, Ventricular Function, Right, Tachycardia, Ventricular, Death, Sudden, Cardiac, Electrophysiology, Syncope
< Back to Listings